Plasminogen activator inhibitor-1

被引:65
作者
Gils, A [1 ]
Declerck, PJ [1 ]
机构
[1] Catholic Univ Louvain, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium
关键词
PAI-1; serpin; fibrinolysis; thrombosis;
D O I
10.2174/0929867043364595
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plasminogen activator inhibitor-1 (PAI-1) is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator. Consequently, PAI-1 plays an important role in cardiovascular diseases (mainly through inhibition of t-PA) and in cell migration and tumor development (mainly through inhibition of u-PA). As a member of the serpin superfamily, PAI-1 shares important structural properties with other serpins. However, PAI-1 also exhibits unique conformational and functional properties. The current paper provides an overview of the knowledge on PAI-1 gathered since its discovery two decades ago. We are discussing (a) its structural properties and their subsequent association with the functional properties, (b) its role in a wide variety of (patho)physiological processes and (c) a number of strategies to interfere with its functional properties eventually aiming at pharmacological modulation of this risk factor.
引用
收藏
页码:2323 / 2334
页数:12
相关论文
共 200 条
[1]  
Abrahamsson T, 1996, THROMB HAEMOSTASIS, V75, P118
[2]   MECHANISMS CONTRIBUTING TO THE CONFORMATIONAL AND FUNCTIONAL FLEXIBILITY OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 [J].
AERTGEERTS, K ;
DEBONDT, HL ;
DERANTER, CJ ;
DECLERCK, PJ .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (10) :891-897
[3]   Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction [J].
Al-Shwaft, KA ;
de Meester, A ;
Pirenne, B ;
Col, JJ .
AMERICAN HEART JOURNAL, 2003, 145 (02) :217-225
[4]   PURIFICATION AND CHARACTERIZATION OF NATURAL AND RECOMBINANT HUMAN-PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) [J].
ALESSI, MC ;
DECLERCK, PJ ;
DEMOL, M ;
NELLES, L ;
COLLEN, D .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 175 (03) :531-540
[5]   Production of plasminogen activator inhibitor 1 by human adipose tissue - Possible link between visceral fat accumulation and vascular disease [J].
Alessi, MC ;
Peiretti, F ;
Morange, P ;
Henry, M ;
Nalbone, G ;
JuhanVague, I .
DIABETES, 1997, 46 (05) :860-867
[6]  
ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644
[7]  
Andreasen PA, 1999, THROMB HAEMOSTASIS, V81, P407
[8]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[9]  
2-Z
[10]   Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-trial [J].
Angeja, BG ;
Alexander, JH ;
Chin, R ;
Li, X ;
Barron, HV ;
Armstrong, PW ;
Granger, CB ;
Van de Werf, F ;
Gibson, CM .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (11) :1240-1245